Patient Story

Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News

Inherited Eye Diseases October 27, 2017

Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.

Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News

Related Articles

Retina Foundation is Major Center for Next Phase of Gene Therapy for X-Linked Retinitis Pigmentosa: SKYLINE Join Us in Celebration of 35 Years! Promising Results From Ongoing Phase 1/2 Clinical Trial for X-Linked Retinitis Pigmentosa (XLRP) Clinical Center of Innovation for Age-Related Macular Degeneration Who Are The Brothers In Toyota’s Super Bowl 2022 Commercial? 
Mailicon
Get the Latest Updates

Sign up to receive emails from Retina Foundation that will keep you up-to-date on our research and events.

  • This field is for validation purposes and should be left unchanged.
Contact Us

Contact Us

  • This field is for validation purposes and should be left unchanged.
x

Please check all that apply:

How did you learn about the
Retina Foundation?

  • Please check all that apply:
  • This field is for validation purposes and should be left unchanged.
Contact Us

Request an Appointment

Please complete this form if you are interested in speaking to a member of our team about your AMD.

all fields required

DOWNLOAD Printable Form